EIR Biopharma filed for a New York Stock Exchange IPO to raise $17.1 million to fund development of a preclinical eye-disease drug.
Longevity News
EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund developm...
Source: FierceBiotech - All • Published: 20 Feb 2026, 11:32
Continue exploring
Related longevity signals
TechCrunchMichael Polansky is training an AI model on skin that’s still aliveReport on a startup combining living human skin tissue maintenance with AI to accelerate discovery of new topical cosmetic compounds and testing workflows.Lifespan.ioA Million-Person Study Finds a Protective Metabolic GeneHuman genetics research exploring metabolic regulation and disease risk, previewing an article that examines gene-based discoveries and potential therapeutic pathways.PR NewswireAureka Biotechnologies Raises US$100 Million Series B to Build a Biological World Model for Drug DiscoveryA biotech funding story about a startup scaling AI-native drug discovery and building biological foundation models; a look at its R&D strategy and platform.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.